azacitidinum - search results

celgene pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - a)intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), b)chronic myelomonocytic leukemia (cmmol 10%-29% marrow blasts without myeloproliferative disorder)), c) acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who). in whom allogenic stem cell transplantation is not indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

onureg azacitidine 300 mg film-coated tablet blister pack

celgene pty ltd - azacitidine, quantity: 300 mg - tablet, film coated - excipient ingredients: mannitol; silicified microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3350; iron oxide black - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

onureg azacitidine 200 mg film-coated tablet blister pack

celgene pty ltd - azacitidine, quantity: 200 mg - tablet, film coated - excipient ingredients: silicified microcrystalline cellulose; mannitol; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; macrogol 3350 - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

azacitidine sandoz

sandoz new zealand limited - azacitidine 100mg - powder for injection - 100 mg - active: azacitidine 100mg excipient: mannitol - azacitidine sandoz is indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),